Koji Haratani

12PUBLICATIONS
123CO-AUTHORS
Molecular targetsNanomedicinePredictive and prognostic markersHaematological tumoursGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|May 02, 2026
PTPN2 inhibition unleashes response to STING agonism in head and neck squamous cell cancer.

|Feb 18, 2026
miR126-mediated alteration of vascular integrity in Rett syndrome.

Tatsuya Osaki, Zhengpeng Wan, Koji Haratani

|Jul 29, 2025
Clinical and molecular landscape of metastatic extramammary Paget's disease.

Satomi Watanabe, Koji Haratani, Tomohiro Nakayama

|Apr 09, 2025
Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with MET Rearrangements.

Seshiru Nakazawa, Federica Pecci, Igor Odintsov

|Mar 23, 2024
Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancer.

Koji Haratani, Atsushi Nakamura, Nobuaki Mamesaya

|Jan 16, 2024
TREX1 Inactivation Unleashes Cancer Cell STING-Interferon Signaling and Promotes Antitumor Immunity.

Tetsuo Tani, Haritha Mathsyaraja, Marco Campisi

Pageof 2

Frequent Collaborators

5 joint publications

Marco Campisi

4 joint publications

Hidetoshi Hayashi

3 joint publications

David A Barbie

3 joint publications

Ravindra Uppaluri